Kyle Bass PTAB institution success rate swings past 50%
The Patent Trial and Appeal Board has instituted four of the Coalition for Affordable Drugs’ IPR petitions challenging Celgene patents, bringing the total number its petitions instituted to seven and greatly shifting the success rate of what one law firm calls the “PTAB Crashers”
The Patent Trial and Appeal Board (PTAB) on October 27 instituted four inter partes review (IPR) petitions filed by the Coalition of Affordable Drugs against two Celgene patents covering its Revlimid, Pomalyst and Thalomid treatments. The same day the Board...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.